Pfizer Withheld Crucial Data In Lipitor Patent Filing, Ranbaxy Claims
Pfizer Inc. withheld crucial scientific data that might have influenced the patent review board's decision to grant the drug maker a second patent for Lipitor, attorneys for Indian generics maker Ranbaxy...To view the full article, register now.
Already a subscriber? Click here to view full article